Recent News

• 04.10.2025 - Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
• 04.10.2025 - Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
• 04.02.2025 - Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
• 04.02.2025 - Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
• 03.25.2025 - Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
• 03.25.2025 - Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
• 03.13.2025 - Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
• 03.13.2025 - Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
• 03.06.2025 - Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
• 03.06.2025 - Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

Recent Filings

• 04.04.2025 - 8-K Current report
• 04.04.2025 - 8-K Current report
• 04.03.2025 - EFFECT Notice of Effectiveness
• 04.02.2025 - 8-K Current report
• 03.28.2025 - POS AM Post-Effective amendments for registration statement
• 03.20.2025 - 8-K Current report
• 03.13.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.13.2025 - 8-K Current report
• 03.13.2025 - EX-99.1 EX-99.1